Catheter-directed therapy with the FlowTriever system for intermediate-high and high-risk pulmonary embolism: a single-centre experience
Netherlands Heart Journal · 2025-01 · 33 (1) · 14-25
DOI: 10.1007/s12471-024-01916-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Netherlands Heart Journal, online erschienen am 10.12.2024. Verfasst von Einar A Hart und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. Einarhart88@gmail.com. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pulmonary embolism is an important cause of preventable mortality. Treatment strategies depend on risk stratification. High-risk patients, and some intermediate-high-risk patients, require urgent reperfusion therapy. Systemic thrombolysis (ST) is the effective first-choice treatment in these patients; however, the high risk of bleeding complications is a major drawback. In this single-centre retrospective cohort study, we report our experience with the FlowTriever thrombosuction system as an alternative or adjunct to ST in intermediate-high and high-risk pulmonary embolism.
Methods
Demographic and clinical data of all patients treated with the FlowTriever system from December 2021 until March 2024 were retrieved from the electronic medical records. Primary outcomes were technical success rate, 30-day all-cause mortality and major bleeding.
Results
Twenty-one patients were treated with the FlowTriever system, 14 of whom were considered high risk. The technical success rate was 100%. Thirty-day all-cause mortality was 29% and major bleeding was recorded in 5 patients (24%), of which one bleeding event was related to the FlowTriever procedure. A significant reduction was seen in mean pulmonary arterial pressure and right ventricular end-diastolic dimension.
Conclusion
In intermediate-high and high-risk pulmonary embolism patients with ST treatment failure or a contraindication for ST, the FlowTriever thrombosuction system seems to be a minimally invasive alternative treatment modality with low complication rates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. Einarhart88@gmail.com.
- Department of Intensive Care, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Internal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Pulmonology, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Zitieren
APA
Hart, E. A., Eenhoorn, P., Nijkeuter, M., Ruigrok, D., van der Heijden, J. J., Voskuil, M., Liu, T. K. K., Balder, J. W., van de Hoef, T. P., van der Harst, P., Kraaijeveld, A. O., & Dickinson, M. G. (2025). Catheter-directed therapy with the FlowTriever system for intermediate-high and high-risk pulmonary embolism: a single-centre experience. Netherlands Heart Journal, 33(1), 14-25. https://doi.org/10.1007/s12471-024-01916-1
Vancouver
Hart EA, Eenhoorn P, Nijkeuter M, Ruigrok D, van der Heijden JJ, Voskuil M, et al. Catheter-directed therapy with the FlowTriever system for intermediate-high and high-risk pulmonary embolism: a single-centre experience. Netherlands Heart Journal. 2025;33(1):14-25. doi:10.1007/s12471-024-01916-1
BibTeX
@article{Hart2025,
author = {Hart, Einar A and Eenhoorn, Paul and Nijkeuter, Mathilde and Ruigrok, Dieuwertje and van der Heijden, Joris J and Voskuil, Michiel and Liu, Tommy K K and Balder, Jan Willem and van de Hoef, Tim P and van der Harst, Pim and Kraaijeveld, Adriaan O and Dickinson, Michael G},
title = {Catheter-directed therapy with the FlowTriever system for intermediate-high and high-risk pulmonary embolism: a single-centre experience},
journal = {Netherlands Heart Journal},
year = {2025},
volume = {33},
number = {1},
pages = {14--25},
doi = {10.1007/s12471-024-01916-1}
}
EUVIMED